56 results about "Overall survival" patented technology

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The invention provides a glioblastoma patient lifetime prediction method and system, and relates to the technical field of intelligent medical treatment, and the method comprises the steps: obtaining and coding a digital full-slice image of a patient; screening high-information-content image blocks based on information entropy; executing a dendritic calculation rule and a structural plasticity rule through internal learnable dendritic neurons by using a dendritic morphological neural calculation model, and extracting global and local features from the image blocks; fusing the features through feature fusion neurons to obtain depth features; and finally, predicting the total lifetime through the output neurons. By simulating hierarchical calculation and plasticity of neuron dendrites, a double-level feature learning model capable of integrating global context and local details of a full-slice image at the same time is constructed, and the technical problems that an existing prediction method is insufficient in feature integration and limited in model calculation structure are effectively solved. And more comprehensive and accurate prediction of the lifetime of the glioblastoma patient is realized.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a cancer vaccine (e.g., mRNA vaccine against a tumor) in combination with a bispecific antigen-binding molecule comprising a first antigen-binding domain that binds specifically CD28 and a second antigen-binding domain that binds specifically to a tumor-associated antigen (TAA). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and / or increased overall survival, as compared to a subject administered the cancer vaccine as monotherapy.

The application discloses that 5-oxoproline can be used as a biomarker for diagnosing chemotherapy-induced cardiomyopathy, and for the first time provides a blood metabolic marker for assisting in predicting and early diagnosing chemotherapy drug-induced cardiomyopathy, which has high accuracy and diagnostic reference value. By accurately determining the content of the small molecule metabolic marker 5-oxoproline in blood, the diagnosis of early myocardial injury induced by chemotherapy drugs will no longer completely rely on conventional non-specific myocardial injury markers and imaging methods, but will rely on the content change of metabolic products in the blood of patients as an objective index, thus advancing the time window for discovering subclinical myocardial injury, significantly improving the early diagnosis detection rate, simplifying the diagnosis process, providing an opportunity for early intervention, helping to prevent or reverse the further aggravation of chemotherapy-induced cardiomyopathy, and thus improving the overall survival prognosis of tumor patients.

The disclosure relates to methods, compositions, and kits for detecting and analyzing surface marker displaying agents (SMDAs). The disclosure further relates to methods for detecting, diagnosing, monitoring response to treatment or recurrence, or predicting overall survival, progression-free survival or duration of response in a subject suspected of having colorectal cancer (CRC) comprising performing one or more assays on at least one biological sample from the subject to detect one or more specific populations of EVs.

The invention belongs to the technical field of biomedicine and molecular diagnosis, and particularly relates to a combined marker and a risk scoring model for prognosis prediction of lung adenocarcinoma based on lactylation related genes as well as a construction method and application of the combined marker and the risk scoring model, and the combined marker comprises the following 12 genes: ANGPTL4, ITGA6, SOD1, CCL20, FKBP3, DECR1, SEMA3C, TRIM28, VEGFC, TNNC2, CRTAC1 and HGF. On the basis of sequencing data of large-scale lung adenocarcinoma samples, a group of lactylation related genes closely related to the total lifetime are systematically screened out, and a risk scoring model is constructed. According to the model, survival risk layering can be accurately carried out on the lung adenocarcinoma patient, and reliable reference is provided for clinical treatment strategy formulation and individualized management. In addition, the lactylation related genes are newly found, and the lactylation process in the lung adenocarcinoma can be understood.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

The invention provides an application of an immune related gene in prognosis prediction of melanoma. On the basis of sequencing data of large-scale melanoma samples, a group of immune-related genes closely related to the total lifetime are systematically screened out, and a risk scoring model is constructed. According to the model, survival risk layering can be accurately carried out on melanoma patients, and reliable reference is provided for clinical treatment strategy formulation and individualized management.

The invention relates to the technical field of medical artificial intelligence prediction, and discloses a method for predicting the total lifetime of bladder cancer through a multi-modal fusion deep learning model. The method includes quality control and normalized preprocessing by collecting clinical, image and genetic data of a patient. Then multi-modal features are extracted, and high-value features are screened out through feature importance evaluation to form an enhanced feature set; a feature interaction network is adopted to learn a complex dependency relationship among different modal features, and deep fusion is realized to generate integrated feature representation. And finally, constructing a depth prediction model based on the representation, and capturing a mapping relation between the depth prediction model and the total lifetime. Through the deep fusion and feature screening technology, multi-modal information is integrated, the defect that a traditional method neglects interaction between modals is overcome, and the accuracy and reliability of predicting the total lifetime of the bladder cancer patient are improved.

The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a cancer vaccine (e.g., mRNA vaccine against a tumor) in combination with a bispecific antigen-binding molecule comprising a first antigen-binding domain that binds specifically CD28 and a second antigen-binding domain that binds specifically to a tumor-associated antigen (TAA). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and / or increased overall survival, as compared to a subject administered the cancer vaccine as monotherapy.

The present application relates to the application of IFIT1 in the prognosis evaluation of low adhesion type gastric cancer patients. The present application firstly finds that the expression level of IFIT1 and the level of neutrophil infiltration can more accurately reflect the immune characteristics of the microenvironment of low adhesion type gastric cancer tissue and the high and low risk of overall survival of gastric cancer patients after operation, and IFIT1 in TANs is an effective biomarker for the prognosis of this type of gastric cancer. Based on this, a detection kit for low adhesion type gastric cancer patients is provided, which can judge the prognosis of low adhesion type gastric cancer patients and the effect of immunotherapy by detecting the expression amount of IFIT1 in the microenvironment of gastric cancer. If the expression amount of IFIT1 is up-regulated, it indicates that the prognosis of low adhesion type gastric cancer patients and the effect of immunotherapy are not good. The kit can reflect the immune characteristics of the microenvironment of low adhesion type gastric cancer tissue and the risk of overall survival after operation, and is helpful for guiding the decision-making of patient immunotherapy and implementing precision treatment in clinical practice.

The disclosure relates to methods, compositions, and kits for detecting and analyzing surface marker displaying agents (SMDAs). The disclosure further relates to methods for detecting, diagnosing, monitoring response to treatment or recurrence, or predicting overall survival, progression-free survival or duration of response in a subject suspected of having colorectal cancer (CRC) comprising performing one or more assays on at least one biological sample from the subject to detect one or more specific populations of EVs.

The application belongs to the field of biological pharmacy, and particularly relates to application of a Caerin polypeptide combined with a dendritic cell vaccine in preparation of a drug for treating breast cancer. The application finds that F1 / F3 significantly inhibits proliferation of 4T-1 cells and induces cell death in vitro, significantly inhibits growth of a primary tumor, reduces lung metastasis, and prolongs overall survival in vivo, and inoculation of a DC vaccine loaded with a tumor-related antigen can reduce tumor growth and enhance T cell activation in draining and non-draining lymph nodes. Compared with a vaccine loaded with a whole antigen (DCV1), a DC vaccine (DCV2) combined with F1 / F3 induced 'programmed death antigen' exhibits stronger anti-tumor activity, although TNF-alpha and IL-12 secretion thereof is lower. Therefore, the application combines the F1 / F3 polypeptide with the DCV2 to prepare a drug for treating breast cancer, effectively improves the treatment effect on the tumor, and highlights the importance of a combined immunotherapy strategy.

This invention belongs to the field of tumor prognostic assessment technology and discloses a prognostic assessment system for lung adenocarcinoma based on the p53 R248Q mutation. The system includes a detection module, a data input module, a risk stratification module, and a result output module, which sequentially realize data interaction and flow. These four modules achieve unidirectional data flow and bidirectional interactive verification, forming a closed-loop prognostic assessment system. The functions of each module support each other and progress progressively. The core objective is to accurately screen patients with EGFR / p53 R248Q co-mutated lung adenocarcinoma and achieve individualized survival risk stratification based on the clinical cohort's overall survival (OS) quartile method. This system realizes the full-process implementation of molecular testing, patient screening, risk assessment, and clinical application.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

The invention discloses a colorectal cancer risk scoring method based on liquid-liquid phase separation. The method comprises the following steps: firstly, acquiring tumor and normal tissue data of a colorectal cancer patient and a liquid-liquid phase separation related gene set from a database, and screening differential expression genes; and then, screening out prognostic genes of AQP11, CCDC34, HADH, FBL and RAB15 by using a single factor Cox regression method, an LASSO regression method and a step AIC method, so as to obtain the prognostic genes of AQP11, CCDC34, HADH, FBL and RAB15. And constructing a risk scoring model based on the expression values and regression coefficients of the prognosis genes, calculating risk scores of the patients, and dividing the patients into a high-risk group and a low-risk group according to medians. And finally, analyzing the total lifetime difference, gene mutation, tumor microenvironment and drug sensitivity of the two groups. The invention provides a new tool and basis for prognosis evaluation and individualized treatment of colorectal cancer patients.

Provided are a cell membrane-expressed IL-15 fusion protein and a use thereof in cell therapy. The provided fusion protein comprises an IL-15Rα signal peptide, IL-15, an IL-15Rα sushi domain, and a transmembrane region; and a cell modified with the fusion protein can achieve efficient expression of IL-15 on the surface of a cell membrane, can effectively avoid side effects caused by the secretion and expression of IL-15, and is safe and controllable. An immune cell modified with a chimeric antigen receptor containing the membrane-expressed IL-15 fusion protein has a stronger tumor killing function, higher IFN-γ secretion, and a greater proliferative capacity; after treatment with lactic acid and TGF-β which are abundant in a tumor microenvironment, the immune cell retain a strong tumor killing function; and the immune cell can activate the anti-tumor function of immune cells other than the immune cell. The constructed immune cell can improve the therapeutic effect against tumors, prolong the duration of disease remission, and improve overall survival in patients.

The present invention pertains to the use of small molecules in the treatment of cancer. These compounds, which are small-molecule Furin inhibitors, show an ability to enhance sensitivity to immunotherapy and radiotherapy treatments, leading to tumor regression in mice and improved overall survival. Treatment of cancer cells with these compounds resulted in the elimination of the capacity for tumor cells and organoids to grow and invade. These results demonstrate the interest of using these small-molecule Furin inhibitors as therapeutic interventions for cancer patients.

This invention discloses the application of fruquintinib combined with PD-1 monoclonal antibody in maintenance therapy for HER-2 negative advanced gastric cancer / geoesophageal junction adenocarcinoma, belonging to the field of tumor treatment technology. This invention targets HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma, specifically patients who achieve disease control after 3 months of first-line induction therapy with PD-1 monoclonal antibody combined with oxaliplatin, followed by maintenance therapy with fruquintinib combined with PD-1 monoclonal antibody without chemotherapy. The maintenance therapy regimen provided by this invention improves patients' quality of life and prolongs overall survival while delaying disease progression, and has significant clinical implications.

The application provides application of ABHD17C in diagnosis, treatment and prognosis of KRAS mutant pancreatic ductal carcinoma. It is found that the expression level of ABHD17C protein in KRAS mutant pancreatic ductal carcinoma patients is significantly higher than that in KRAS wild type pancreatic ductal carcinoma patients and healthy controls, and is significantly negatively correlated with the expression level of ALOX15B. In addition, the overall survival and recurrence-free survival of KRAS mutant pancreatic ductal carcinoma patients with high expression of ABHD17C protein are significantly shorter than those of KRAS mutant pancreatic ductal carcinoma patients with low expression of ABHD17C protein, and the difference has statistical significance. Moreover, silencing or inhibiting the expression of ABHD17C protein can promote ferroptosis of KRAS mutant pancreatic ductal carcinoma cells, can significantly inhibit the occurrence and development of KRAS mutant pancreatic ductal carcinoma, can inhibit the growth of tumor, and can effectively prolong the overall survival. It is indicated that the ABHD17C protein can be used as a diagnostic and prognostic biomarker of KRAS mutant pancreatic ductal carcinoma, and can be used as a specific treatment target of KRAS mutant pancreatic ductal carcinoma.

There is a very high interest in identifying effective targets to attenuate the programmed cell removal (PrCR) of tumor cells by macrophages. The present inventors have determined that the cyclin-dependent kinase inhibitor p21 protein is a strong modulator of macrophage-mediated PrCR. Moreover, they have shown that adoptive transfer of monocytes overexpressing p21 induces macrophage PrCR and a shift from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and significantly improves the overall survival of mice engrafted with cancer cells. Accordingly, the present invention relates to therapeutic compositions comprising monocytes overexpressing the cyclin-dependent kinase inhibitor p21 protein, and to their use for treating a mammal suffering from cancer, in particular leukemia.

The invention relates to the technical field of medical image processing. The invention discloses a habitat imaging-based gastric cancer neoadjuvant chemotherapy curative effect prediction method and a habitat imaging-based gastric cancer neoadjuvant chemotherapy curative effect prediction system, and the method comprises the following steps: S1, obtaining pre-treatment CT and clinical pathology information, and marking the maximum tumor area and upper and lower layers; s2, dividing the marked region into habitat sub-regions with different biological characteristics through habitat imaging; and S3, performing prognosis analysis on the habitat subregion, screening independent prognosis features related to survival, and generating a habitat subregion image. And S4, constructing a joint attention model, inputting images of the marked area and the habitat subarea, predicting the curative effect and the total lifetime, and obtaining a survival score. And S5, integrating clinical pathological information and survival scores, performing prognosis analysis, constructing a column graph, and evaluating correlation. After a CT image label before treatment is obtained, habitat imaging is used for dividing subareas, related images are generated, the model is input in a combined mode, tumor heterogeneity is revealed, and the curative effect is predicted.

The invention relates to the technical field of medical information, and discloses a non-small cell lung cancer immunotherapy prognosis risk assessment method and system and a medium, and the method comprises the steps: obtaining clinical data including clinical variables, progression-free lifetime (PFS) and total lifetime (OS); taking each clinical variable as a hierarchical index to divide patient subgroups, and screening out hierarchical indexes with significant differences; then, aiming at each subgroup divided by the screened hierarchical indexes, quantifying prognosis influence of other clinical variables on the corresponding subgroup by adopting a risk regression model; and finally, screening out determinants with prognosis values according to a quantification result, dividing the determinants into different prognosis recommendation levels, and constructing a risk assessment matrix. According to the method, through a two-stage screening strategy of firstly identifying the effective hierarchical indexes and then analyzing the prognosis factors, evaluation deviation caused by generalization of local effective factors or neglecting of global non-significant factors is avoided, so that the accuracy and clinical practicability of prognosis evaluation are remarkably improved.

The application belongs to the technical field of biomarker diagnostic products, and relates to application of UBALD2 as a marker in a hepatocellular carcinoma diagnostic product, and application of a substance for detecting UBALD2 expression level in an in-vitro detection reagent, a detection kit and / or an in-vitro prognosis evaluation product. The application proves that UBALD2 is highly expressed in hepatocellular carcinoma tissues from two aspects of protein level and mRNA level, and indicates that UBALD2 can be used as one of molecular indexes reflecting the occurrence and development state of hepatocellular carcinoma. The application proposes that high expression of UBALD2 is related to poor overall survival of patients, and is related to a later T stage, and indicates that the substance for detecting UBALD2 can be used for prognosis risk evaluation, prognosis stratification and clinical auxiliary judgment products of hepatocellular carcinoma patients, and provides a reference basis for individualized management of patients.

The present application relates to P21-expressing monocytes for cancer cell therapy. Identification of effective targets that mitigate programmed cell clearance (PrCR) of tumor cells by macrophages has a very high interest. The present inventors have determined that the cyclin-dependent kinase inhibitor p21 protein is an emphasized regulatory factor of macrophage mediated PrCR. In addition, they also show that mononuclear cells that adoptively transfer overexpression p21 induce in vivo macrophages PrCR and transitions from anti-inflammatory phenotypes to pro-inflammatory phenotypes, delay cancer progression and significantly increase the overall survival rate of mice in which cancer cells are transplanted. Thus, the present invention relates to therapeutic compositions comprising monocytes overexpressing the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, in particular leukemia.

The application relates to the field of molecular biomedical technology, and discloses a method, system and device for evaluating recurrence risk and prognosis of a resectable non-small cell lung cancer (NSCLC) patient based on plasma circulating free DNA (cfDNA) fragmentomics. The method comprises the following steps: obtaining plasma cfDNA of the NSCLC patient and performing high-throughput sequencing; extracting fragment end mode characteristic values (CsFMA) of GATA3 and CEP57 genes from the sequencing data, which are CsFMA.GATA3 and CsFMA.CEP57 respectively; inputting the characteristic values into a risk score model; calculating an individual risk value; stratifying the patient into a high-risk group and a low-risk group according to the risk value, so as to predict disease-free survival and overall survival. The application discloses a strong correlation between specific fragmentomic characteristics of GATA3 and CEP57 genes and recurrence and prognosis of NSCLC, and the constructed model can effectively predict recurrence risk and prognosis. The application provides a non-invasive and accurate new tool for resectable NSCLC recurrence and prognosis stratification and individualized treatment decision-making.

This disclosure relates to methods for treating or inhibiting tumor growth, wherein the method includes selecting a subject with cancer and administering to the subject in need a combination of a therapeutically effective amount of a targeted immune cytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain binding to PD1) and a TAAxCDS bispecific antibody. Compared to subjects receiving targeted immune cytokines as monotherapy, the combination therapy has shown improved antitumor efficacy, increased duration of tumor control, and / or increased overall survival.

The application discloses a biomarker for predicting the prognosis of extrahepatic cholangiocarcinoma and application thereof, and relates to the technical field of biological medicine.The biomarker is C-X-C motif chemokine ligand 11.The application adopts an enzyme-linked immunosorbent assay method to detect the concentration of CXCL11 in bile of an extrahepatic cholangiocarcinoma patient, so as to predict the prognosis of the patient.The research result shows that the higher the concentration of CXCL11 in the bile is, the lower the overall survival rate of the patient in 1 year and 3 years is, which indicates that the prognosis of the extrahepatic cholangiocarcinoma is poor.Therefore, the application finds that the CXCL11 in the bile can be used as an effective biomarker for predicting the prognosis of the extrahepatic cholangiocarcinoma.This finding provides a brand-new biomarker for evaluating the prognosis of cholangiocarcinoma, and has important clinical significance and scientific research value for accurately predicting the prognosis risk of the patient and expanding the treatment strategy of the cholangiocarcinoma.

This invention belongs to the fields of disease diagnosis, prognosis, and molecular biology, specifically relating to the application of spermine synthase (SMS) in the diagnosis, prognosis, and prediction of response to immune checkpoint blockade (ICB) therapy in hepatocellular carcinoma (HCC). Research revealed that, compared to normal liver tissue, the expression of spermine synthase (SMS) is significantly upregulated in HCC; and high SMS expression is associated with poor clinicopathological features of prognosis. Furthermore, compared to the low SMS expression group, HCC patients in the high SMS expression group had significantly shorter overall survival, disease-specific survival, and progression-free survival, thus SMS overexpression predicts unfavorable outcomes. Simultaneously, SMS overexpression affects immune cell infiltration in HCC patients, leading to poor immune checkpoint blockade (ICB) responses and poor treatment efficacy for HCC. In conclusion, SMS can serve as a biomarker for the diagnosis and prediction of clinical outcomes in HCC, and also as a biomarker for predicting ICB treatment response.